Tetracycline Use Associated With Lower C. diff Infection Risk

Researchers assessed CDI and tetracycline use in an effort to delineate antibiotic choices
Researchers assessed CDI and tetracycline use in an effort to delineate antibiotic choices

This article is written live from ID Week 2017 Annual Meeting in San Diego, CA. MPR will be reporting news on the latest findings from leading experts in infectious diseases. Check back for more news from IDWeek 2017.


SAN DIEGO—Patients exposed to tetracyclines might face a 38% lower risk of Clostridium difficile infection (CDI), according to results of a systematic review and meta-analysis presented at IDWeek 2017.

"Tetracycline use (particularly doxycycline) may be associated with a decreased risk of future development of CDI compared to other antibiotics," reported Raseen Tariq, MBBS, of the Mayo Clinic in Rochester, MN, and coauthors.

The study authors utilized Medline, Embase, and Web of Science to search for studies evaluating the risk of CDI after tetracycline use and compared it to the risk associated with the use of other antibiotics.

The review included data obtained from 4 case-control studies and 2 cohort studies that reported associations between CDI and use of tetracyclines or other antibiotics. 

Their meta-analysis of data from the studies demonstrated that tetracyclines were associated with decreased risk of CDI compared to other antibiotics (OR, 0.62; 95% CI, 0.47–0.81; P=.0005). There was significant heterogeneity between the studies (I2 =53%) and no publication bias was observed. 

"Clinicians may consider tetracyclines such as doxycycline over alternative antimicrobials where appropriate to reduce risk of CDI," the researchers concluded.

For continuous infectious disease news coverage from the IDWeek 2017, check back to MPR's IDWeek page for the latest updates.

Reference:

Tariq R, Cho J, Kapoor S, et al. Tetracyclines are Associated with a Reduced Risk of Clostridium difficile Infection: A Systematic Review and Meta-analysis. Poster presented at IDWeek; October 4–8, 2017; San Diego, CA. http://www.idweek.org.